We’re proud to have supported the first of three Patient and Family Seminars for indolent systemic mastocytosis (ISM), hosted by Medscape/WebMD in partnership with The Mast Cell Disease Society, Inc. (TMS) and the American Initiative in Mast Cell Diseases. These educational seminars offer a unique space for patients and their families to connect with each other and learn directly from leading medical experts, fostering a deeper understanding of ISM and helping them confidently navigate their journey. Read more from Jessica Fraser, Executive Director at TMS, following the first seminar.
Blueprint Medicines
Biotechnology Research
Cambridge, Massachusetts 50,874 followers
Striving to improve and extend patients' lives
About us
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
- Website
-
http://www.blueprintmedicines.com
External link for Blueprint Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2011
- Specialties
- targeted therapy, systemic mastocytosis, breast cancer, allergy/inflammatory, hematology/oncology, solid tumors, drug design, and mast cell biology
Locations
-
Primary
Get directions
45 Sidney St
Cambridge, Massachusetts 02139, US
-
Get directions
Baarerstrasse 8
Zug, 6300, CH
Employees at Blueprint Medicines
Updates
-
Today, we announced our Q3 2024 financial results. Join our live investor webcast at 8 a.m. ET or read our press release here: https://bit.ly/4eYhBCK
-
-
That's a wrap! The #BlueCrew had a great time engaging with allergists and immunologists at #ACAAI24 to discuss our latest research in indolent systemic mastocytosis. We also supported a mast cell-focused educational symposium with Dr. Matthew Giannetti and Dr. Andrew White as part of our efforts to continue improving the understanding of SM and other mast cell diseases.
-
-
As we build on our deep understanding of mast cell disorders, we continue looking for opportunities to engage with healthcare professionals who see patients every day. At #ACAAI24, we look forward to interacting with the allergy/inflammation community and mast cell disease experts to strengthen our collective knowledge of indolent systemic mastocytosis. If you're attending the meeting, check out where you can find us below:
-
We're proud to honor the strength and resilience of people living with systemic mastocytosis and other mast cell diseases. As we commit to advancing research for these diseases, we aim to serve as true partners to the patient community.
Today marks Mastocytosis and Mast Cell Diseases Awareness Day, a day dedicated to recognizing the experiences and resilience of those living with these conditions. Whether you’ve had a diagnosis for years, are newly navigating the journey, or live with a rare subtype, you are not alone. We come together to raise awareness, share knowledge, and advocate for a future where understanding is stronger and support is more accessible. At TMS, we are proud to stand with the international community in the ongoing fight for greater awareness and brighter days ahead. Together, we hold hope. Together, we make progress.
-
We’re pleased to share that we've earned five Culture Excellence Awards from Top Workplaces and were named in the top 25% of companies for Strong Values and Employee Appreciation, based on feedback directly from our #BlueCrew. We're proud to be recognized for our commitment to nurturing our culture and providing opportunities for employees to thrive and grow in their careers. Congratulations, Blue Crew!
-
Today, we celebrate International Mastocytosis and Mast Cell Diseases Awareness Day alongside a community of patients, families, advocacy organizations and disease experts. In partnership with the mast cell disease community, we've pioneered systemic #mastocytosis (SM) research and the development of innovative medicines for more than a decade. Our vision is a future in which individuals with SM can pursue their life goals unimpeded. We know that advancing science is just one piece of the puzzle. In our blog, read how we work to strengthen the understanding of SM and other mast cell diseases through patient support initiatives, collaborations and storytelling: https://bit.ly/4f5dHYm #MCAD
-
-
That's a wrap on #CoreValuesWeek 2024! Yesterday, we culminated an inspiring week as our global #BlueCrew participated in volunteer activities in their local areas and through partnerships with Boston Cares, Catie's Closet, Inc and Zharity. At Blueprint Medicines, we lead with Thoughtfulness in our approach to sustainable community service, ensuring our environmental, community and social care initiatives create a meaningful impact.
-
-
At Blueprint Medicines, storytelling is an integral part of our culture and an avenue for us to learn, inspire and connect with one another. This year's #CoreValuesWeek Storytelling Event focused on "Seizing the Opportunity," where #BlueCrew members across the company shared how important moments from their personal and professional lives shaped their career and ultimately led them to Blueprint. Thank you to our storytellers in Cambridge and Zug!
-
-
At Blueprint Medicines, our core value of Patients First guides us to maintain an intense focus on improving patients' lives. This #CoreValuesWeek, we were honored to hear from two women living with systemic mastocytosis and from Jenna Benn Shersher, founder and CEO of Twist Out Cancer, the partner organization for our #ColorsOfSM art initiative. Hearing from patients directly increases our understanding of their unique experiences, and we're motivated to continue supporting those affected throughout their disease journey.
-
Similar pages
Browse jobs
Stock
BPMC
NASDAQ
20 minutes delay
$99.63
2.08 (2.132%)
- Open
- 100
- Low
- 98.405
- High
- 101.48
Data from Refinitiv
See more info on